Skip to main content
Industry News
Kite CAR T-cell therapy wins conditional EU approval

Kite, a division of Gilead Sciences, has been granted conditional marketing authorization by the European Medicines Agency for Tecartus, or brexucabtagene autoleucel, a chimeric antigen receptor T-cell therapy for relapsed or refractory mantle cell lymphoma. The treatment was approved in the US in July.

Full Story: